Solara Active Pharma Sciences Ltd Stock Price Today (NSE: SOLARA)
Fundamental Score
Solara Active Pharma Sciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Solara Active Pharma Sciences Ltd share price today is ₹502.60, down 1.66% on NSE/BSE as of 7 August 2026. Solara Active Pharma Sciences Ltd (SOLARA) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹2.76K (Cr). The 52-week high for SOLARA share price is ₹712.00 and the 52-week low is ₹422.00. The company has a Return on Equity (ROE) of -0.13% and a debt-to-equity ratio of 0.55.
Solara Active Pharma Sciences Ltd Share Price Chart — NSE/BSE Historical Performance
Solara Active Pharma Sciences Ltd share price chart: -9.31% return over the past month. 52-week high ₹712.00, 52-week low ₹422.00.
Solara Active Pharma Sciences Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹511.15 | ₹514.30 | ₹497.60 | ₹502.60 | 1.50L (Cr) | |
| ₹514.15 | ₹522.30 | ₹509.00 | ₹511.10 | 84.17K (Cr) | |
| ₹523.95 | ₹523.95 | ₹511.20 | ₹514.65 | 83.61K (Cr) | |
| ₹518.85 | ₹522.80 | ₹514.05 | ₹520.65 | 1.28L (Cr) | |
| ₹522.85 | ₹523.65 | ₹513.00 | ₹515.85 | 1.11L (Cr) | |
| ₹510.00 | ₹516.00 | ₹506.75 | ₹513.55 | 1.15L (Cr) | |
| ₹509.95 | ₹516.50 | ₹501.30 | ₹506.20 | 1.14L (Cr) | |
| ₹504.35 | ₹509.00 | ₹495.20 | ₹507.00 | 1.94L (Cr) | |
| ₹493.00 | ₹509.15 | ₹471.55 | ₹505.00 | 5.79L (Cr) | |
| ₹562.00 | ₹562.00 | ₹515.70 | ₹536.15 | 4.78L (Cr) |
Solara Active Pharma Sciences Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹522.85 | ₹523.95 | ₹497.60 | ₹502.60 | -3.87% | |
| ₹576.10 | ₹601.00 | ₹471.55 | ₹513.55 | -10.86% | |
| ₹532.70 | ₹620.35 | ₹520.10 | ₹575.70 | +8.07% | |
| ₹495.80 | ₹606.40 | ₹492.20 | ₹532.70 | +7.44% | |
| ₹440.00 | ₹518.00 | ₹440.00 | ₹495.80 | +12.68% | |
| ₹452.00 | ₹479.00 | ₹422.00 | ₹425.55 | -5.85% | |
| ₹511.00 | ₹549.00 | ₹440.20 | ₹462.20 | -9.55% | |
| ₹564.95 | ₹588.05 | ₹496.05 | ₹506.20 | -10.40% | |
| ₹514.60 | ₹641.00 | ₹510.00 | ₹564.95 | +9.78% | |
| ₹603.00 | ₹647.00 | ₹502.30 | ₹514.25 | -14.72% | |
| ₹603.60 | ₹621.00 | ₹575.50 | ₹599.80 | -0.63% | |
| ₹616.95 | ₹712.00 | ₹597.00 | ₹602.95 | -2.27% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Solara Active Pharma Sciences Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Solara Active Pharma Sciences Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of SOLARA across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Robust Profit Growth (516.19%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Strong Revenue Growth (41.86%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Risk Factors
7 factors identified
Below-Average Return on Equity (-0.13%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (4.86%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Limited Growth History (-3.27% CAGR)
Observation: Below-average 5-year sales growth trajectory.
Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.
Weak Interest Coverage (0.98x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability.
Negative Free Cash Flow (₹-61.57 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
High Share Pledging Risk (36.57%)
Observation: Significant promoter share pledging creates potential overhang.
Analysis: High pledging levels may create selling pressure during market downturns.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Solara Active Pharma Sciences Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Solara Active Pharma Sciences Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Solara Active Pharma Sciences LtdSolara Active P...Selected✓ SOLARA • 541540 | 8/100 | ₹502.60₹503 | ₹2763.61₹2763.61 | — — | -0.13%Poor -0.13% Poor | 4.86%Poor 4.86% Poor | 0.55Good 0.6 Good | — — | -3.27%Poor -3.27% Poor | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Solara Active Pharma Sciences Ltd PE Ratio History
Historical price-to-earnings ratio for SOLARA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹0.14 | ₹564.95 | 4035.4x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Solara Active Pharma Sciences Ltd Dividend History
Annual cash dividends paid by SOLARA — dividend yield N/A
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2022 | ₹10.78 Cr |
| FY 2021 | ₹19.73 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Solara Active Pharma Sciences Ltd Quarterly Performance
Latest quarterly metrics for SOLARA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
41.86%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
516.19%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
-3.27%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
N/A
Compounded annual net profit growth over 5 years
Solara Active Pharma Sciences Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for SOLARA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Solara Active Pharma Sciences Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Solara Active Pharma Sciences Ltd (SOLARA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Solara Active Pharma Sciences Ltd
About SOLARA (Solara Active Pharma Sciences Ltd)
Solara Active Pharma Sciences Ltd is a prominent player in the global pharmaceutical landscape, deeply involved in the creation and delivery of essential pharmaceutical building bl...ocks. The company operates as a multifaceted entity, engaging in the meticulous manufacturing, precise production, and sophisticated processing of active pharmaceutical ingredients (APIs). With a commitment to quality and innovation, Solara plays a crucial role in the pharmaceutical value chain, ensuring the availability of high-quality APIs that underpin the production of a wide array of medications. Their extensive operations span across continents, reflecting their dedication to serving diverse healthcare needs on a global scale. Solara's reach extends beyond mere manufacturing, encompassing the entire lifecycle of pharmaceutical ingredients. They expertly formulate these APIs, skillfully blend scientific expertise with technological advancements to create products that meet stringent regulatory standards. Their commercial activities are equally robust, involving the strategic sale, import, and export of APIs, enabling them to reach key markets across India, Asia Pacific, Europe, North and South America. This global network is supported by a sophisticated merchandising, distribution, and trading infrastructure, ensuring seamless delivery and accessibility of their products to pharmaceutical manufacturers worldwide. Solara's portfolio encompasses a diverse range of APIs, targeting a wide spectrum of therapeutic areas. They supply essential ingredients for medications addressing critical conditions such as amyotrophic lateral sclerosis, as well as those used in anesthesia. Their offerings also include APIs for treatments related to hyperlipidemia, arrhythmia, asthma, hypertension, inflammation, Parkinson's disease, and retroviral infections. This breadth of therapeutic coverage highlights Solara's commitment to contributing to improved health outcomes and their dedication to supporting the development of innovative and effective pharmaceutical products across various medical disciplines.
Company Details
Key Leadership
Corporate Events
SOLARA Share Price: Frequently Asked Questions
What is the current share price of Solara Active Pharma Sciences Ltd?
Solara Active Pharma Sciences Ltd (SOLARA) trades at ₹502.60 on NSE and BSE. Market cap ₹2.76K (Cr). Educational data only.
What is the P/E ratio of Solara Active Pharma Sciences Ltd?
Solara Active Pharma Sciences Ltd has a P/E of N/Ax vs industry average 34.89x.
What is the Bull Run score for Solara Active Pharma Sciences Ltd?
Solara Active Pharma Sciences Ltd has a Bull Run score of 8/100 based on 25+ financial parameters.
Does Solara Active Pharma Sciences Ltd pay dividends?
Solara Active Pharma Sciences Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Solara Active Pharma Sciences Ltd?
Solara Active Pharma Sciences Ltd has ROE of -0.13%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Solara Active Pharma Sciences Ltd?
Solara Active Pharma Sciences Ltd has debt-to-equity of 0.55.
Is Solara Active Pharma Sciences Ltd a good investment?
Bull Run gives Solara Active Pharma Sciences Ltd a score of 8/100. This is not investment advice — consult a SEBI-registered advisor.